Why is it when Jerome Powell sneezes, the ASX 200 catches a cold?

The Federal Reserve chair's comments might be impacting the Aussie share market…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The word inflation written with a ticking time bomb.

Image source: Getty Images

Key points

  • The ASX 200 took a hit following comments from the United States Federal Reserve chair Jerome Powell
  • Expectations of interest rates being lifted in the US earlier is spilling over into the ASX
  • Major Australian banks now forecast rate hikes to occur this year

It's been a tough few days for the S&P/ASX 200 Index (ASX: XJO). On Thursday, the market took another nose-dive after the United States Federal Reserve chair Jerome Powell made hawkish remarks about inflation.

The market is worried that central banks will be forced to bring forward interest rate increases faster than expected. This has left the ASX 200 in pain, as investors take note of Powell's signals.

But why have Australian shares been reacting to the comments of Jerome Powell? After all, he is the chair of a central bank in the United States, not Australia.

Two markets cut from the same cloth

While the decisions made by Jerome Powell involve the monetary policy of a different country, Australia — and much of the developed world — is in the same boat.

Whether it is a product of globalisation, or a coincidence, Australia and the United States are both experiencing increased inflation. This in itself isn't much of a surprise — in fact, central banks were targeting an increase in inflation.

A rebound in inflation would indicate a strengthening of the economy. For example, an increase in wages can suggest a reduction in unemployment. Furthermore, higher living costs may infer households are spending more money — a sign consumer confidence is higher.

However, inflation remains a balancing act for central banks. Let it run too hot and costs can get out of hand. But, if the hammer is brought down too hard and fast, all the economic strengthening can quickly be undone.

This is a tight rope that central banks have been trying to walk since the beginning of the COVID-19 pandemic. To date, Jerome Powell has opted to let inflation push above the target range. Similarly, our own chair of the Reserve Bank of Australia, Philip Lowe, has been cautious to suggest any rate rise in the near future.

Although, this has suddenly changed for Powell after US inflation reached 7% in December. In response, the chair hinted at its first interest rate rise occurring as early as March this year. The abrupt change of plans to the previously peddled roadmap has caught the ASX 200 index off guard.

Now, ASX investors are wary an interest rate rise could be happening sooner than previously expected in Australia.

What ASX 200 banks are forecasting for interest rates?

Soon after Jerome Powell's revised rate expectations, more revisions flowed from the major banks on their forecasts for Australia rates.

The National Australia Bank Ltd. (ASX: NAB) revealed to investors yesterday that the RBA could move to lift rates in November this year. Following this, additional increases in interest rates could happen in December 2022 and February 2023.

Meanwhile, another ASX 200 bank — Westpac Banking Corp (ASX: WBC) beat the Federal Reserve to the punch line and announced its expectations for the first rate increase in August this year. The major bank provided this forecast on 20 January, nearly a week before Powell's comments.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

Time to sell written on a clock.
Broker Notes

Sell alert! Why this expert is calling time on Magellan and Ramsay Health Care shares

A leading expert forecasts growing headwinds for Magellan and Ramsay Health Care shares. But why?

Read more »

A beautiful ocean vista is shown with a woman whose back is to the camera holding her arms up in triumph as she stands at the top of a rock feeling thrilled that ASX 200 shares are reaching multi-year high prices today
ASX Share Market News

Record breaker! The ASX 200 just hit a fresh all-time high

Investors just sent the ASX 200 into uncharted territory.

Read more »

Pilot on the phone looking distraught.
Broker Notes

Sell alert! Why this expert is ditching Qantas shares for this ASX 200 defence stock

A leading expert is selling Qantas shares and buying this surging ASX 200 defence stock instead. But why?

Read more »

An old-fashioned news boy stands on a stool and yells through a microphone in an open field.
ASX Share Market News

Why is everyone talking about Domino's, Light & Wonder and BHP shares on Wednesday?

BHP, Light & Wonder, and Domino’s shares are turning heads today. But why?

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
ASX Share Market News

Earnings preview: can Cochlear shares rebound?

A decade low share price meets a make-or-break result.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Broker Notes

Morgans tips a 600%+ return for this ASX biotech stock

Good clinical study progress has the broker bullish on this company.

Read more »